The global facial rejuvenation market size expected to reach USD 26,440.13 million at a CAGR of 20.85% by 2027. Facial rejuvenation is a combination of medical and cosmetic procedure that is carried out the youthful appearance to the human face. Facial rejuvenation is carried by either minimally invasive or non-invasive treatment which aims to restore skin elasticity and enables maintain a youthful appearance in the neck and face region. Facial rejuvenation plays a vital role in skin protection from sun damage. In young ages, human naturally defend their bodies from sun damage by neutralization of free radicals which are reactive oxygen atoms damage the skin’s collagen. However, human bodies lose the resistance towards ultra violet radiations in older age. The signs of sun damage include wrinkles, enlarged pores, sagging skin, freckling or spotting and spider veins. Many treatments such as microabrasion, dermabrasion, topical creams, chemical peels, dermal fillers, and cosmetic surgery are available for the protection of skin from sun damage. Market players are adopting various key strategies that include acquisitions and mergers, collaborations, agreements, product approvals, and launching of new products to increase share in the facial rejuvenation market. For instance, in June 2009, Anika Therapeutics, signed an exclusive U.S. distribution agreement with Palo Alto, Coapt Systems, Inc. for its aesthetic dermatology franchise. Coapt Systems’ suite of bioabsorbable implants for use in facial aesthetic and rejuvenation procedures is highly complementary to Anika’s injectable filler that corrects lines and wrinkles on the face. In addition, in July 2008, Johnson & Johnson received U.S. Food and Drug Administration clearance to market Evolence, an injectable collagen for treating facial wrinkles. Moreover, in April 2016, Merz Pharma made a strategic venture investment in Cytrellis Biosystems, for developing a new class of non-surgical products to combat sagging skin associated with aging.